Skip to main content
Premium Trial:

Request an Annual Quote

Evosep, Thermo Fisher Scientific Strike Comarketing Deal for Clinical Proteomics Offerings

NEW YORK — Proteomics-focused liquid chromatography firm Evosep said on Monday that it has signed an agreement to comarket its sample separation technology with Thermo Fisher Scientific's mass spectrometry instruments.

Odense, Denmark-based Evosep said that one aspect of the deal includes offering its end-to-end sample preparation workflows along with Thermo Fisher's Orbitrap Astral mass spectrometer and related services.

The Orbitrap Astral MS was launched in mid-2023 and offers dramatic improvement over the previous state of the art, providing the ability to measure many thousands of proteins at levels of throughput necessary to conduct large-scale studies.

Financial and other terms of the partnership were not disclosed.

"This comarketing agreement represents a pivotal moment in advancing mass spectrometry-based clinical proteomics for transformative impacts on healthcare," Evosep CEO Morten Bern said in a statement. "We aim to empower researchers in unlocking new dimensions of biomarker discovery, diagnostics, and therapeutic development."